TNF Inhibitor denied as non-formulary by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Denies TNF Inhibitors as Non-Formulary

Anthem Blue Cross organizes its covered drugs into a tiered formulary. A non-formulary denial means the specific TNF inhibitor prescribed is not included on your plan's current drug list, or it sits on a restricted tier that requires additional authorization. This sometimes happens because Anthem has a preferred agent within the same drug class (often a biosimilar or a contracted originator product) that must be tried first.

Non-formulary denials are appealable — and often winnable — when there is a documented clinical reason why the preferred alternative is not appropriate for your specific situation. Plans are also required to maintain an exceptions process, which is a separate pathway from a standard formulary appeal.

## Federal Appeal Framework

• Formulary exception request: Before or alongside an appeal, submit a formulary exception request. Under ACA regulations, plans must process exceptions when a covered alternative would be clinically contraindicated or when every covered alternative has been tried and failed.
• Internal appeal (ERISA §503 / ACA §2719): If the exception is denied, file a formal internal appeal within the timeframe on your denial letter, supported by clinical documentation.
• External independent review: After internal exhaustion on ACA-compliant plans. The window is generally up to approximately four months from final internal denial. IRO decisions are binding.
• Expedited review: Request if delay creates serious health risk.

## Documentation to Gather

1. Diagnosis and indication — specialist notes confirming the diagnosis and the specific FDA-approved indication for the requested agent. 2. Prior use of formulary alternatives — for each TNF inhibitor or biologic Anthem lists as a preferred alternative, document whether it was tried (with dates and outcomes) or why it is clinically inappropriate for this patient, per the prescriber's judgment. 3. Clinical distinction — any chart-documented reason the requested agent is preferable (prior response, tolerability profile, administration route, or other individualized clinical factor), stated by the prescriber. 4. Prescriber medical-necessity and exception letter — written statement from the prescribing clinician addressing: why the non-formulary agent is medically necessary, why each formulary alternative is not appropriate, and the clinical basis for that determination. 5. Anthem's current formulary and coverage policy — download the exact formulary tier document and the applicable drug coverage policy to understand which agents are listed as preferred.

## Criteria-Mapping Structure

| Formulary Exception Requirement | Supporting Documentation | |---|---| | [Copy each exception criterion from Anthem's policy or member handbook] | [Chart note, date, and clinician statement addressing each] |

Your prescriber should: - Reference the FDA-approved prescribing information for the requested TNF inhibitor - Cite the applicable guideline organization (e.g., ACR, AGA, AAD) as supporting this agent for the diagnosis - Explicitly address each formulary alternative Anthem lists and why it is not suitable

Verify all clinical criteria, dosing, and eligibility requirements against the current FDA prescribing label and Anthem's current published formulary and medical/coverage policy before submitting.